LEAD INVESTIGATORS

(Lead PI of the Protein Biochemistry Core and Structural Biology Core) is a world-recognized crystallographer with major contributions to structure-based drug design, the study of membrane proteins and HIV integrase and viral proteases. 

(Lead PI of the Screening Core) is widely known for innovations in high-throughput screening (HTS) and fragment discovery and for 14 years has co-run the UCSF Small Molecule Discovery Center with Adam Renslo.

(Lead PI of the Medicinal Chemistry Core) has a Pharma med chem background and deep experience in hit-to-lead and lead optimization, with a longstanding interest in antimicrobial chemotherapy.

(Lead PI of the Structural Biology Core) is a leader in developing Cryo-EM techniques and their applications.

(Lead PI of the Integrative Modeling Core) is a world expert on integrative modeling of protein machines and developed widely used software, such as IMP and MODELLER.

(Lead PI of the In Vitro Virology Core and In Vivo Virology Core) is the director of the Gladstone Institute of Virology and recognized for her contributions to HIV Cure research and the pathogenesis of hepatitis C virus, zika virus and SARS-CoV-2 infections.

(Lead PI of the In Vivo Virology Core and In Vitro Virology Core) is the director of one of five NIAID-funded Centers of Excellence for Influenza Research and Surveillance and an expert on the molecular biology of negative-strand RNA viruses.

(Lead PI of the Proteomics Core) is a junior faculty at UCSF, an expert in mass spectrometry and Director of the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at UCSF/Gladstone.

(Lead PI of Project 1 and Project 4) is among the world’s foremost chemical biologists and has had an outsize impact on drug discovery for difficult targets.

(Lead PI of Project 2) is a world leader in protease structure-function, with a longstanding interest in antivirals.

(Lead PI of Project 3) is an expert in peptide chemistry, protein design, and drug discovery.

(Co-I of Project 2, Project 4, Project 5, the Screening Core, and Medicinal Chemistry Core) is an expert in molecular docking, structure-based inhibitor discovery and artifact detection in early discovery.

(Co-I of Project 1 and the In Vitro Virology Core) is a Nobel laureate renowned for the discovery of CRISPR and RNA-protein studies.

(Co-I of Project 2) is an expert in antiviral drug discovery and his crystal structures of HIV-1 RT drove the development of two anti-HIV drugs, etravirine and rilpivirine.

(Co-I of the In Vitro Virology Core) is recognized for generating recombinant arenaviruses, influenza and zika viruses with plasmid-based reverse genetic approaches. His lab has access to a maximum containment BSL-4 laboratory.

(Co-I of Project 2) is the world leader in characterizing the inhibition mechanisms of remdesivir and molnupiravir and focuses on studying and targeting RNA viral replication, with applications to Ebola, Nipah, Lassa, RSV, and influenza.

(Co-I of Project 4) focuses on developing new high throughput biophysical and biochemical characterization and screening methods to discover selective inhibitors of methyltransferases.

(Co-I of the In Vitro Virology Core and In Vivo Virology Core) monitors and predicts the evolution of RNA viruses for developing vaccines and antivirals.

(Co-I of the In Vitro Virology Core and In Vivo Virology Core) aims to understand the molecular and cellular aspects of antiviral immunity in insects.

(Co-I of the Structural Biology Core) is an electron microscopist who redefined the resolution limits of single-particle Cryo-EM to rival the atomic resolution of X-ray crystallography.

(Co-I of the Biochemistry Core and Integrative Modeling Core) combines computer science, physics, chemistry, mathematics, engineering and biology to engineer new bioactive molecules.

(Co-I of Project 6 and the Structural Biology Core) is a QBI Fellow who leverages Cryo-EM and high-throughput X-ray crystallography for drug discovery.

(Co-I of the In Vitro Virology Core) was recently ranked in the top 5 female NIH-funded investigators and studies innate immune evasion by coronaviruses, zika, HIV, influenza, chikungunya and dengue using human primary cell systems.

(Co-I of the Proteomics Core) has expertise in proteomics techniques with a focus on crosslinking (XL)-MS.

(Co-I of the In Vitro Virology Core and Administrative Core) is a senior scientist and the Project Manager of QBI’s infectious disease portfolio, with expertise in molecular virology and immunomodulation during infection.

(Co-I of Project 2) is an accomplished biochemist and structural biologist with experience in viral protein structures and the regulation of HIV transcription.

(Co-I of the Administrative Core) is a molecular systems virologist, and project manager with experience in science outreach and DEI programs.

.